Effects of peptide YY on insulin release stimulated by 2-deoxyglucose and neuropeptides in dogs

Y. S. Guo, Pomila Singh, J. F. DeBouno, J. C. Thompson

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Peptide YY (PYY) is a hormone released from gut after a meal. The objective of this study was to determine the effect of PYY on insulin release stimulated by either 2-deoxyglucose (2-DG) or neuropeptides in conscious dogs with gastric and doudenal fistulas. In contrast experiments dogs received either 2-DG (75 mg/kg i.v. bolus) or atropine (25 μg/kg bolus followed by 20 μg/kg/h i.v.) plus 2-DG (75 mg/kg i.v.) or bethanechol (80 μg/kg/h i.v.) or vasoactive intestinal peptide (VIP, 4 μg/kg i.v. bolus) or gastrin releasing peptide (GRP, 400 pmol/kg/h i.v.) or tetragastrin (G4, 100 μg/dog i.v. bolus). On separate days, PYY was also infused intravenously in combination with one of the above stimulants. Given intravenously, PYY (200, 400 pmol/kg/h) significantly inhibited 2-DG stimulated-insulin secretion in a dose-dependent fashion. This inhibitory effect also existed in the presence of atropine. Peptide YY (400 pmol/kg/h) depressed the insulin levels in response to GRP or G4 but failed to inhibit bethanechol- and VIP-stimulated insulin release. After administration of the above stimulants, PYY did not modify the blood sugar concentrations. These results demonstrated that PYY might inhibit the cephalic phase of insulin release from dogs triggered by 2-DG and by the neuropeptides GRP and G4. Thus, PYY may play a negative feedback regulatory role on insulin release.

Original languageEnglish (US)
Pages (from-to)128-134
Number of pages7
JournalPancreas
Volume3
Issue number2
StatePublished - 1988

Fingerprint

Peptide YY
Deoxyglucose
Neuropeptides
Dogs
Insulin
Bethanechol
Atropine
Tetragastrin
Gastric Fistula
Gastrin-Releasing Peptide
Vasoactive Intestinal Peptide
Meals
Blood Glucose
Head
Hormones

ASJC Scopus subject areas

  • Endocrinology
  • Gastroenterology

Cite this

Effects of peptide YY on insulin release stimulated by 2-deoxyglucose and neuropeptides in dogs. / Guo, Y. S.; Singh, Pomila; DeBouno, J. F.; Thompson, J. C.

In: Pancreas, Vol. 3, No. 2, 1988, p. 128-134.

Research output: Contribution to journalArticle

Guo, Y. S. ; Singh, Pomila ; DeBouno, J. F. ; Thompson, J. C. / Effects of peptide YY on insulin release stimulated by 2-deoxyglucose and neuropeptides in dogs. In: Pancreas. 1988 ; Vol. 3, No. 2. pp. 128-134.
@article{67267a70a2ea4a2e9db48d11e3eae81e,
title = "Effects of peptide YY on insulin release stimulated by 2-deoxyglucose and neuropeptides in dogs",
abstract = "Peptide YY (PYY) is a hormone released from gut after a meal. The objective of this study was to determine the effect of PYY on insulin release stimulated by either 2-deoxyglucose (2-DG) or neuropeptides in conscious dogs with gastric and doudenal fistulas. In contrast experiments dogs received either 2-DG (75 mg/kg i.v. bolus) or atropine (25 μg/kg bolus followed by 20 μg/kg/h i.v.) plus 2-DG (75 mg/kg i.v.) or bethanechol (80 μg/kg/h i.v.) or vasoactive intestinal peptide (VIP, 4 μg/kg i.v. bolus) or gastrin releasing peptide (GRP, 400 pmol/kg/h i.v.) or tetragastrin (G4, 100 μg/dog i.v. bolus). On separate days, PYY was also infused intravenously in combination with one of the above stimulants. Given intravenously, PYY (200, 400 pmol/kg/h) significantly inhibited 2-DG stimulated-insulin secretion in a dose-dependent fashion. This inhibitory effect also existed in the presence of atropine. Peptide YY (400 pmol/kg/h) depressed the insulin levels in response to GRP or G4 but failed to inhibit bethanechol- and VIP-stimulated insulin release. After administration of the above stimulants, PYY did not modify the blood sugar concentrations. These results demonstrated that PYY might inhibit the cephalic phase of insulin release from dogs triggered by 2-DG and by the neuropeptides GRP and G4. Thus, PYY may play a negative feedback regulatory role on insulin release.",
author = "Guo, {Y. S.} and Pomila Singh and DeBouno, {J. F.} and Thompson, {J. C.}",
year = "1988",
language = "English (US)",
volume = "3",
pages = "128--134",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Effects of peptide YY on insulin release stimulated by 2-deoxyglucose and neuropeptides in dogs

AU - Guo, Y. S.

AU - Singh, Pomila

AU - DeBouno, J. F.

AU - Thompson, J. C.

PY - 1988

Y1 - 1988

N2 - Peptide YY (PYY) is a hormone released from gut after a meal. The objective of this study was to determine the effect of PYY on insulin release stimulated by either 2-deoxyglucose (2-DG) or neuropeptides in conscious dogs with gastric and doudenal fistulas. In contrast experiments dogs received either 2-DG (75 mg/kg i.v. bolus) or atropine (25 μg/kg bolus followed by 20 μg/kg/h i.v.) plus 2-DG (75 mg/kg i.v.) or bethanechol (80 μg/kg/h i.v.) or vasoactive intestinal peptide (VIP, 4 μg/kg i.v. bolus) or gastrin releasing peptide (GRP, 400 pmol/kg/h i.v.) or tetragastrin (G4, 100 μg/dog i.v. bolus). On separate days, PYY was also infused intravenously in combination with one of the above stimulants. Given intravenously, PYY (200, 400 pmol/kg/h) significantly inhibited 2-DG stimulated-insulin secretion in a dose-dependent fashion. This inhibitory effect also existed in the presence of atropine. Peptide YY (400 pmol/kg/h) depressed the insulin levels in response to GRP or G4 but failed to inhibit bethanechol- and VIP-stimulated insulin release. After administration of the above stimulants, PYY did not modify the blood sugar concentrations. These results demonstrated that PYY might inhibit the cephalic phase of insulin release from dogs triggered by 2-DG and by the neuropeptides GRP and G4. Thus, PYY may play a negative feedback regulatory role on insulin release.

AB - Peptide YY (PYY) is a hormone released from gut after a meal. The objective of this study was to determine the effect of PYY on insulin release stimulated by either 2-deoxyglucose (2-DG) or neuropeptides in conscious dogs with gastric and doudenal fistulas. In contrast experiments dogs received either 2-DG (75 mg/kg i.v. bolus) or atropine (25 μg/kg bolus followed by 20 μg/kg/h i.v.) plus 2-DG (75 mg/kg i.v.) or bethanechol (80 μg/kg/h i.v.) or vasoactive intestinal peptide (VIP, 4 μg/kg i.v. bolus) or gastrin releasing peptide (GRP, 400 pmol/kg/h i.v.) or tetragastrin (G4, 100 μg/dog i.v. bolus). On separate days, PYY was also infused intravenously in combination with one of the above stimulants. Given intravenously, PYY (200, 400 pmol/kg/h) significantly inhibited 2-DG stimulated-insulin secretion in a dose-dependent fashion. This inhibitory effect also existed in the presence of atropine. Peptide YY (400 pmol/kg/h) depressed the insulin levels in response to GRP or G4 but failed to inhibit bethanechol- and VIP-stimulated insulin release. After administration of the above stimulants, PYY did not modify the blood sugar concentrations. These results demonstrated that PYY might inhibit the cephalic phase of insulin release from dogs triggered by 2-DG and by the neuropeptides GRP and G4. Thus, PYY may play a negative feedback regulatory role on insulin release.

UR - http://www.scopus.com/inward/record.url?scp=0023820739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023820739&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 128

EP - 134

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 2

ER -